Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19
Copyright © 2021 Elsevier B.V. All rights reserved..
Epidemiological and clinical evidence suggests that Bacille Calmette-Guérin (BCG) vaccine induced trained immunity protects against non-specific infections. Multiple clinical trials are currently underway to assess effectiveness of the vaccine in the coronavirus disease 2019 (COVID-19). However, the durability and mechanism of BCG trained immunity remain unclear. Here, an integrative analysis of available epidemiological transcriptomic data related to BCG vaccination and respiratory tract viral infections as well as of reported transcriptomic alterations in COVID-19 is presented toward addressing this gap. Results suggest that the vaccine induces very long-lasting transcriptomic changes that mimic viral infections by, consistent with the present concept of trained immunity, upregulation of antiviral defense response, and oppose viral infections by, inconsistent with the concept, downregulation of myeloid cell activation. These durability and mechanistic insights argue against possible indiscriminate use of the vaccine and activated innate immune response associated safety concerns in COVID-19, in that order.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:783 |
|---|---|
| Enthalten in: |
Gene - 783(2021) vom: 30. Mai, Seite 145574 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sharma, Abhay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 14.04.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gene.2021.145574 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32293625X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32293625X | ||
| 003 | DE-627 | ||
| 005 | 20231225183109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gene.2021.145574 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM32293625X | ||
| 035 | |a (NLM)33737124 | ||
| 035 | |a (PII)S0378-1119(21)00168-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sharma, Abhay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a Epidemiological and clinical evidence suggests that Bacille Calmette-Guérin (BCG) vaccine induced trained immunity protects against non-specific infections. Multiple clinical trials are currently underway to assess effectiveness of the vaccine in the coronavirus disease 2019 (COVID-19). However, the durability and mechanism of BCG trained immunity remain unclear. Here, an integrative analysis of available epidemiological transcriptomic data related to BCG vaccination and respiratory tract viral infections as well as of reported transcriptomic alterations in COVID-19 is presented toward addressing this gap. Results suggest that the vaccine induces very long-lasting transcriptomic changes that mimic viral infections by, consistent with the present concept of trained immunity, upregulation of antiviral defense response, and oppose viral infections by, inconsistent with the concept, downregulation of myeloid cell activation. These durability and mechanistic insights argue against possible indiscriminate use of the vaccine and activated innate immune response associated safety concerns in COVID-19, in that order | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCG vaccine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a Trained immunity | |
| 650 | 4 | |a Transcriptome | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Gene |d 1979 |g 783(2021) vom: 30. Mai, Seite 145574 |w (DE-627)NLM000233951 |x 1879-0038 |7 nnns |
| 773 | 1 | 8 | |g volume:783 |g year:2021 |g day:30 |g month:05 |g pages:145574 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gene.2021.145574 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 783 |j 2021 |b 30 |c 05 |h 145574 | ||